{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:45:57Z","timestamp":1791463557339,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1990,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["1K23CA121994"],"award-info":[{"award-number":["1K23CA121994"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Komen for the Cure Catalytic","award":["KG090341"],"award-info":[{"award-number":["KG090341"]}]},{"name":"Komen for the Cure Grant SAC","award":["100004 (AMG)"],"award-info":[{"award-number":["100004 (AMG)"]}]},{"name":"American Cancer Society Research Scholar","award":["121329-RSG-11-187-01-TBG (AMG)"],"award-info":[{"award-number":["121329-RSG-11-187-01-TBG (AMG)"]}]},{"name":"Anderson's Cancer Center Support","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1093\/annonc\/mdu124","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T00:34:47Z","timestamp":1395794087000},"page":"1122-1127","source":"Crossref","is-referenced-by-count":86,"title":["Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"A.M.","family":"Gonzalez-Angulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Akcakanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Palla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.B.","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Brewster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.K.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Moulder-Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Litton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Dryden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.F.","family":"Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-A.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.B.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu124_bb0010","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu124_bb0015","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update","volume":"24","author":"Kaufmann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu124_bb0020","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu124_bb0025","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric Berstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu124_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdu124_bb0035","doi-asserted-by":"crossref","first-page":"8397","DOI":"10.1158\/0008-5472.CAN-04-1612","article-title":"Phosphatidylinositol 3\u2032-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells","volume":"64","author":"Lee","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu124_bb0040","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu124_bb0045","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjc.6604851","article-title":"Safety and pharmacokinetics of paclitaxel and the mTOR inhibitor everolimus in advanced solid tumors","volume":"100","author":"Campone","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdu124_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1559-0275-8-11","article-title":"Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer","volume":"8","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin Proteomics"},{"key":"10.1093\/annonc\/mdu124_bb0055","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND. 163","volume":"27","author":"Ellard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu124_bb0060","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu124_bb0065","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/annonc\/mdt248","article-title":"Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy","volume":"24","author":"Sohn","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu124_bb0070","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s10549-010-0967-z","article-title":"The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study","volume":"128","author":"Macaskill","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu124_bb0075","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","article-title":"Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor\u2013positive breast cancer","volume":"27","author":"Baselga","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1093\/annonc\/mdu124_bb0080","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","article-title":"Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy","volume":"29","author":"Morrow","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu124_bb0085","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1200\/JCO.2009.27.8549","article-title":"Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab","volume":"28","author":"Andre","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdu124_bb0090","article-title":"Everolimus with paclitaxel plus bevcizumab as first-line therapy for HER2 negative metastatic breast cancer(MBC): a randomized, double blind, placebo controlled phase II trial of the Sarah Cannon Research Institute (SCRI)","volume":"30","author":"Yardley","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu124_bb0095","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ejca.2013.02.027","article-title":"Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin\/cyclophosphamide (EC)\u00b1bevacizumab\u2014results of the randomised GeparQuinto study (GBG 44)","volume":"49","author":"Huober","year":"2013","journal-title":"Eur J Cancer"},{"issue":"suppl:","key":"10.1093\/annonc\/mdu124_bb0100","article-title":"Correlation of molecular alterations with efficacy of everolimus in hormone receptor\u2013positive, HER2-negative advanced breast cancer: results from BOLERO-2","volume":"31","author":"Hortobagyi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu124_bb0105","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-010-0928-6","article-title":"Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer","volume":"122","author":"Sabine","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu124_bb0110","doi-asserted-by":"crossref","first-page":"e53292","DOI":"10.1371\/journal.pone.0053292","article-title":"PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer","volume":"8","author":"Loi","year":"2013","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdu124_bb0115","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","article-title":"PIK3CA\/PTEN mutations and AKT activation as markers of sensitivity to allosteric mTOR inhibitors","volume":"18","author":"Meric-Bernstam","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu124_bb0120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3816\/CGC.2007.n.020","article-title":"Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma","volume":"5","author":"Cho","year":"2007","journal-title":"Clin Genitourin Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:44:11Z","timestamp":1624520651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419365780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0923753419365780"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu124","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}